Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in cl...
Tue, 07 Jul 2026 02:20:00 -0400 - 6 weeks ago
Jun 8, 2026, 12:00 PM EDT - 2 months ago
Jun 4, 2026, 2:35 PM EDT - 2 months ago
May 14, 2026, 2:00 AM EDT - 3 months ago
May 6, 2026, 2:00 AM EDT - 3 months ago
Apr 8, 2026, 2:00 AM EDT - 4 months ago
Mar 9, 2026, 11:20 AM EDT - 5 months ago
2026-03-05T00:00:14.000Z - 5 months ago
Mar 4, 2026, 1:50 PM EST - 5 months ago
Feb 27, 2026, 2:00 AM EST - 6 months ago
Feb 25, 2026, 4:00 PM EST - 6 months ago
Jan 15, 2026, 12:00 PM EST - 7 months ago
Jan 14, 2026, 7:00 AM EST - 7 months ago
Nov 18, 2025, 7:30 AM EST - 9 months ago
Nov 11, 2025, 10:00 AM EST - 10 months ago
Nov 10, 2025, 9:00 AM EST - 10 months ago
Nov 5, 2025, 2:00 AM EST - 10 months ago
Sep 8, 2025, 10:00 AM EDT - 1 year ago
Sep 5, 2025, 12:00 PM EDT - 1 year ago
Sep 3, 2025, 1:00 PM EDT - 1 year ago
Aug 22, 2025, 2:00 AM EDT - 1 year ago